+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo



Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo



Nuclear Medicine and Biology 30(2): 187-190



New glutamatergic drugs are being developed as potential therapies for neurodegenerative disorders, anxiety disorders, and psychoses. The development of effective mGluR radiotracers would provide essential tools with which to probe these sites in living humans, providing critical information about certain disease processes involving the glutamaterigic system and its regulation in humans. As a first step towards this goal, the tritiated form of the high affinity group II metabotropic glutamate receptor (mGluR) antagonist LY341495 [K(D) (mGluR(2)) = 1.67 +/- 0.20 nM, K(D) (mGluR(3)) = 0.75 +/- 0.43 nM] was evaluated to determine its potential to label mGluRs in vivo. Dissection analysis of the regional brain distribution over time of [(3)H]LY341495 in male rats revealed low brain uptake and no significant demonstrable saturable binding of this tracer. A group II mGluR tracer possessing higher affinity than [(3)H]LY341495 and an absence of carboxylic acid groups is likely required for in vivo PET imaging purposes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048993180

Download citation: RISBibTeXText

PMID: 12623118

DOI: 10.1016/s0969-8051(02)00423-7


Related references

3H]LY341495, a highly potent, selective and novel radioligand for labeling Group II metabotropic glutamate receptors. Bioorganic and Medicinal Chemistry Letters 8(14): 1919-1922, 1998

3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics 298(2): 453-460, 2001

LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 37(1): 1-12, 1998

LY341495 as a novel antagonist radioligand for group II metabotropic glutamate receptors Characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology 38(10): 1519-1529, 1999

Evaluation of agonists and antagonists acting at Group I metabotropic glutamate receptors in the thalamus in vivo. Neuropharmacology 38(10): 1505-1510, 1999

Pharmacological characterization of LY341495, a potent antagonist of metabotropic glutamate receptors. Society for Neuroscience Abstracts 23(1-2): 2024, 1997

In vivo pharmacology of the selective metabotropic glutamate receptor antagonist LY341495. Society for Neuroscience Abstracts 25(1-2): 450, 1999

Activation of group III metabotropic glutamate receptors by endogenous glutamate protects against glutamate-mediated excitotoxicity in the hippocampus in vivo. Journal of Neuroscience Research 90(5): 1055-1066, 2012

Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268. Journal of Neurochemistry 117(6): 973-983, 2011

LY341495 and LY366457, group II metabotropic glutamate receptor antagonists, induce locomotor activation in mice. Journal of Psychopharmacology 17(Suppl. 3): A40, 2003

Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45(5): 565-574, 2003

Role of group II metabotropic glutamate receptors 2/3 and group I metabotropic glutamate receptor 5 in developing rat medial vestibular nuclei. Neuroreport 16(12): 1303-1307, 2005

A role for presynaptic group I metabotropic glutamate receptors in the control of glutamate release in the rat striatum An in vivo microdialysis study. British Journal of Pharmacology 123(PROC Suppl. ): 207P, 1998

A comparison of group III metabotropic glutamate receptor agonists and the ability of LY341495 to antagonise their responses on neonatal rat primary afferents. British Journal of Pharmacology 135(Proceedings Suppl.): 92P, 2002

(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors. Bioorganic and Medicinal Chemistry Letters 15(2): 349-351, 2005